Clinical efficacy of transcatheter arterial chemoembolization combined with surgical resection for treating spontaneous rupture of hepatocellular carcinoma
- 1Department of Interventional Radiology,Heze Hospital Affiliated to Shandong First Medical University(Shandong Provincial Hospital Heze Hospital),Heze,Shandong 274000,China
Abstract
Objective To compare the efficacy and survival outcomes of transcatheter arterial chemoembolization(TACE)combined with surgical resection versus surgical resection alone in patients with ruptured hepatocellular carcinoma(HCC),and to investigate their effects on liver function indicators,tumor markers,and quality of life.Methods A total of 120 patients with ruptured HCC admitted to Heze Hospital Affiliated to Shandong First Medical University from May 2021 to May 2023 were retrospectively selected. They were divided into a resection group(n=60)and a combined embolization group(n=60)according to treatment modality. The resection group underwent surgical resection using the Pringle maneuver(hepatic inflow occlusion),while the combined embolization group received TACE in addition to surgical resection. Liver function indicators,serum tumor markers,quality-of-life scores,and prognosis were compared between the two groups. Results After treatment,there were no statistically significant differences in alanine aminotransferase,aspartate aminotransferase,and total bilirubin levels between the two groups(P>0.05). The levels of alpha-fetoprotein,carbohydrate antigen 19-9,and glypican-3 in the combined embolization group were significantly lower than those in the resection group(P<0.05). The Quality of Life-Liver Cancer(QOL-LC)scores increased significantly in both groups after treatment,with the combined embolization group showing significantly higher scores than the resection group(P<0.05). The 1 - year cumulative survival rate was 91.67% in the combined embolization group,which was significantly higher than that(71.67%)in the resection group(log-rank χ2=8.624,P=0.003). The 1-year cumulative progression-free survival rate was also significantly higher in the combined embolization group compared with the resection group(83.33% vs 63.33%,log-rank χ2=7.752,P=0.005). Conclusion TACE combined with surgical resection for patients with ruptured primary HCC can effectively reduce serum tumor marker levels,improve both quality of life and prognosis,and does not aggravate liver function impairment.
Related
- Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma.
- Case Report: Rapidly fatal hepatic portal venous gas following transarterial chemoembolization for hepatocellular carcinoma
- Enhanced Efficacy of Thalidomide‐Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi‐Center Cohort Study
- Neoadjuvant transarterial chemoembolization, camrelizumab, and apatinib for centrally located hepatocellular carcinoma (NEO-CENTACT): study protocol for a phase II trial.
- Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma
BibTeX
@article{defang2026clinical,
title = {{Clinical efficacy of transcatheter arterial chemoembolization combined with surgical resection for treating spontaneous rupture of hepatocellular carcinoma}},
author = {NIU Defang and ZHENG Xu and JI Fang},
journal = {Zhongguo linchuang yanjiu},
year = {2026},
month = oct,
doi = {10.13429/j.cnki.cjcr.2026.10.021},
url = {https://doi.org/10.13429/j.cnki.cjcr.2026.10.021},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical efficacy of transcatheter arterial chemoembolization combined with surgical resection for treating spontaneous rupture of hepatocellular carcinoma
AU - NIU Defang
AU - ZHENG Xu
AU - JI Fang
PY - 2026
DA - 2026/10/26
JO - Zhongguo linchuang yanjiu
DO - 10.13429/j.cnki.cjcr.2026.10.021
UR - https://doi.org/10.13429/j.cnki.cjcr.2026.10.021
AB - Objective To compare the efficacy and survival outcomes of transcatheter arterial chemoembolization(TACE)combined with surgical resection versus surgical resection alone in patients with ruptured hepatocellular carcinoma(HCC),and to investigate their effects on liver function indicators,tumor markers,and quality of life.Methods A total of 120 patients with ruptured HCC admitted to Heze Hospital Affiliated to Shandong First Medical University from May 2021 to May 2023 were retrospectively selected. They were divided into a resection group(n=60)and a combined embolization group(n=60)according to treatment modality. The resection group underwent surgical resection using the Pringle maneuver(hepatic inflow occlusion),while the combined embolization group received TACE in addition to surgical resection. Liver function indicators,serum tumor markers,quality-of-life scores,and prognosis were compared between the two groups. Results After treatment,there were no statistically significant differences in alanine aminotransferase,aspartate aminotransferase,and total bilirubin levels between the two groups(P>0.05). The levels of alpha-fetoprotein,carbohydrate antigen 19-9,and glypican-3 in the combined embolization group were significantly lower than those in the resection group(P<0.05). The Quality of Life-Liver Cancer(QOL-LC)scores increased significantly in both groups after treatment,with the combined embolization group showing significantly higher scores than the resection group(P<0.05). The 1 - year cumulative survival rate was 91.67% in the combined embolization group,which was significantly higher than that(71.67%)in the resection group(log-rank χ2=8.624,P=0.003). The 1-year cumulative progression-free survival rate was also significantly higher in the combined embolization group compared with the resection group(83.33% vs 63.33%,log-rank χ2=7.752,P=0.005). Conclusion TACE combined with surgical resection for patients with ruptured primary HCC can effectively reduce serum tumor marker levels,improve both quality of life and prognosis,and does not aggravate liver function impairment.
SN - 1674-8182
ER -